RSS-Feed abonnieren

DOI: 10.1055/a-2441-4217
Neuroleptic Malignant Syndrome in a 10-Month-Old Ex-Preterm Infant with Delirium

Abstract
In recent times, atypical antipsychotics are increasingly being used in the neonatal intensive care unit (NICU) for the management of neonatal delirium. As the recognition of delirium in NICU infants increases, caution should be exercised with use of antipsychotics for management, given associated adverse effects. Neuroleptic malignant syndrome (NMS) is a rare adverse drug reaction associated with exposure to antipsychotics and other antidopaminergic medications. Most reported cases of NMS in pediatric patients have been in older children on antipsychotic medications. We present a case of a 10-month-old former preterm infant who developed clinical signs suggestive of NMS after exposure to olanzapine for treatment of delirium. Our case report details the clinical course of this infant, delves into the condition, and outlines some useful lessons for the clinician in the identification and management of this rare but life-threatening adverse effect.
Key Points
-
NMS is a rare side effect of antipsychotic medications.
-
Hyperthermia with mental status changes could be due to NMS.
-
Antipsychotics should be used cautiously in infants.
Publikationsverlauf
Eingereicht: 15. Dezember 2023
Angenommen: 12. August 2024
Accepted Manuscript online:
14. Oktober 2024
Artikel online veröffentlicht:
12. November 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Berman BD. Neuroleptic malignant syndrome: a review for neurohospitalists. Neurohospitalist 2011; 1 (01) 41-47
- 2 Henderson VW, Wooten GF. Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade?. Neurology 1981; 31 (02) 132-137
- 3 Kimura G, Kadoyama K, Brown JB. et al. Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database. Int J Med Sci 2015; 12 (02) 135-140
- 4 van Rensburg R, Decloedt EH. An approach to the pharmacotherapy of neuroleptic malignant syndrome. Psychopharmacol Bull 2019; 49 (01) 84-91
- 5 Croarkin PE, Emslie GJ, Mayes TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatry 2008; 69 (07) 1157-1165
- 6 Neuhut R, Lindenmayer JP, Silva R. Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: a review. J Child Adolesc Psychopharmacol 2009; 19 (04) 415-422
- 7 Penugonda AJ, Singh Y, Kattula D, Bhaskar M. Neuroleptic malignant syndrome in a 15-month-old child: a case report. J Clin Psychopharmacol 2023; 43 (05) 455-456
- 8 Carbone JR. The neuroleptic malignant and serotonin syndromes. Emerg Med Clin North Am 2000; 18 (02) 317-325 , x
- 9 Kunz M, Gomes FA, Tramontina JF, Kapczinski F. Late-onset neuroleptic malignant syndrome in a patient using olanzapine. J Clin Psychopharmacol 2007; 27 (03) 303-304
- 10 Strawn JR, Keck Jr PE, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164 (06) 870-876
- 11 Kubo S, Orihara Y, Kitamura O, Ikematsu K, Tsuda R, Nakasono I. An autopsy case of neuroleptic malignant syndrome (NMS) and its immunohistochemical findings of muscle-associated proteins and mitochondria. Forensic Sci Int 2001; 115 (1–2): 155-158
- 12 Keck Jr PE, Caroff SN, McElroy SL. Neuroleptic malignant syndrome and malignant hyperthermia: end of a controversy?. J Neuropsychiatry Clin Neurosci 1995; 7 (02) 135-144
- 13 Ullah W, Cheema MA, Ashfaq A. et al. A rare association of Takotsubo cardiomyopathy with neuroleptic malignant syndrome. J Community Hosp Intern Med Perspect 2020; 10 (02) 133-137
- 14 Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65 (04) 464-470
- 15 Oomura M, Terai T, Sueyoshi K, Shigeno K. Reversible cardiomyopathy as the autonomic involvement of neuroleptic malignant syndrome. Intern Med 2004; 43 (12) 1162-1165
- 16 Velamoor VR. Neuroleptic malignant syndrome. Recognition, prevention and management. Drug Saf 1998; 19 (01) 73-82
- 17 Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. Psychiatr Serv 1998; 49 (09) 1163-1172
- 18 Caroff SN, Mann SC, Sullivan KA, Campbell EC. Neuroleptic malignant syndrome. In: Movement Disorder Emergencies. Springer; 2022: 95-113
- 19 Erermis S, Bildik T, Tamar M, Gockay A, Karasoy H, Ercan ES. Zuclopenthixol-induced neuroleptic malignant syndrome in an adolescent girl. Clin Toxicol (Phila) 2007; 45 (03) 277-280